John Breitner
Overview
Explore the profile of John Breitner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1516
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heneka M, van der Flier W, Jessen F, Hoozemanns J, Thal D, Boche D, et al.
Nat Rev Immunol
. 2024 Dec;
PMID: 39653749
Increasing evidence points to a pivotal role of immune processes in the pathogenesis of Alzheimer disease, which is the most prevalent neurodegenerative and dementia-causing disease of our time. Multiple lines...
2.
Dauar M, Picard C, Labonte A, Breitner J, Rosa-Neto P, Villeneuve S, et al.
J Alzheimers Dis
. 2024 Apr;
98(4):1361-1375.
PMID: 38578887
Background: Apolipoproteins and contactin 5 are proteins associated with Alzheimer's disease (AD) pathophysiology. Apolipoproteins act on transport and clearance of cholesterol and phospholipids during synaptic turnover and terminal proliferation. Contactin...
3.
Ourry V, Binette A, St-Onge F, Strikwerda-Brown C, Chagnot A, Poirier J, et al.
Biol Psychiatry
. 2023 Sep;
95(11):1006-1019.
PMID: 37689129
Epidemiological studies show that modifiable risk factors account for approximately 40% of the population variability in risk of developing dementia, including sporadic Alzheimer's disease (AD). Recent findings suggest that these...
4.
Iturria-Medina Y, Adewale Q, Khan A, Ducharme S, Rosa-Neto P, ODonnell K, et al.
Sci Adv
. 2022 Nov;
8(46):eabo6764.
PMID: 36399579
Alzheimer's disease (AD) is a heterogeneous disorder with abnormalities in multiple biological domains. In an advanced machine learning analysis of postmortem brain and in vivo blood multi-omics molecular data (...
5.
Ozlen H, Binette A, Kobe T, Meyer P, Gonneaud J, St-Onge F, et al.
JAMA Neurol
. 2022 Aug;
79(10):1025-1035.
PMID: 35994280
Importance: Preventive trials of anti-amyloid agents might preferably recruit persons showing earliest biologically relevant β-amyloid (Aβ) binding on positron emission tomography (PET). Objective: To investigate the timing at which Aβ-PET...
6.
Peters R, Breitner J, James S, Jicha G, Meyer P, Richards M, et al.
Alzheimers Dement (N Y)
. 2021 Dec;
7(1):e12202.
PMID: 34934803
Identifying the leading health and lifestyle factors for the risk of incident dementia and Alzheimer's disease has yet to translate to risk reduction. To understand why, we examined the discrepancies...
7.
Rabipour S, Rajagopal S, Yu E, Pasvanis S, Lafaille-Magnan M, Breitner J, et al.
J Alzheimers Dis
. 2020 Jun;
76(1):97-119.
PMID: 32474466
Background: Episodic memory decline is one of the earliest symptoms of late-onset Alzheimer's disease (AD). Older adults with the apolipoprotein E ɛ4 (+APOE4) genetic risk factor for AD may exhibit...
8.
9.
McSweeney M, Binette A, Meyer P, Gonneaud J, Bedetti C, Ozlen H, et al.
Neurology
. 2020 Feb;
94(11):e1190-e1200.
PMID: 32015176
Objective: To investigate relationships between flortaucipir (FTP) uptake, age, and established Alzheimer disease (AD) markers in asymptomatic adults at increased risk of AD. Methods: One-hundred nineteen individuals with a family...
10.
Meyer P, Savard M, Poirier J, Morgan D, Breitner J
Alzheimers Dement
. 2019 Aug;
15(9):1160-1171.
PMID: 31405825
Introduction: We sought biological pathways that explained discordance between Alzheimer's disease (AD) pathology and symptoms. Methods: In 306 Alzheimer's Disease Neuroimaging Initiative (ADNI)-1 participants across the AD clinical spectrum, we...